- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536363
Cri Analog PG1 Effectiveness and Safety in Covid-19 (PGE1-COVID19)
Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
COVID-19 is a public health problem that has spread throughout the world and has forced different scientific societies to consider effective measures to control the increasing spread of the disease. This disease is presumed to follow a virologic pattern similar to SARS-CoV-1 (Severe acute respiratory syndrome coronavirus 1) . The disease spectrum includes asymptomatic stage and pre-symptomatic , mild infection uncomplicated, mild and severe pneumonia and the acute Respiratory distress syndrome (ARDS) constituting the point of no return characterized by ventilatory mechanics preserved with severe refractory hypoxemia. The pulmonary involvement of patients with COVID-19 causes an endothelial injury, which can be associated with changes in vascular permeability, manifesting as thrombotic, venous and arterial disease in patients with COVID-19. Alprostadil, a prostaglandin E1 analog that has a vasodilator mechanism, inhibitory property of platelet aggregation and inducer of bronchodilation, promises to prevent complications of SARS-CoV2. In addition to that Alprostadil has been used in other clinical trials as treatment for the acute respiratory distress syndrome caused by Influenza, in which it showed no harm or benefit, nonetheless the pathophysiology of the acute distress respiratory syndrome caused by Influenza and COVID-19 are similar in macroscopic changes but very different in microscopic changes which is why it is important to evaluate the effectiveness and safety of the administration of intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial, where patients in the intensive care unit of the Fundación Santa Fe de Bogotá are randomized into two groups, where one is going to be treated with standardized treatment after the guidelines recommendations of the Colombian Infectology Society and the other one is going to receive the same standardized treatment and Alprostadil infusion for a maximum of 7 days. During the infusion of the Alprostadil the patient will be carefully monitored by the intensive care unit team. After the Infusion the patient will be followed up for 30 days in which the mortality and hypoxemia resolution will be monitored.
Key words: COVID-19, Prostaglandin E1 Analogue, Alprostadil, Mortality, Acute respiratory distress syndrome
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alonso Vera Torres, MD
- Phone Number: +573107632766
- Email: Alonso.Vera@fsfb.org.co
Study Contact Backup
- Name: Jose De la Hoz, MD
- Phone Number: 3507084846
- Email: jose.delahoz@fsfb.org.co
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient older than 18 years of age
COVID19 diagnosis:
- RT PCR for COVID-19 positive in respiratory tract sample (nasopharyngeal swab, sputum, bronchoalveolar lavage)
- At least 2 of the following symptoms: cough, odynophagia, dyspnea, asthenia, adynamia, gastrointestinal symptoms.
- Findings compatible with viral pneumonia on chest tomography or chest radiography.
- Risk of respiratory deterioration given by at least 1 of the following:
- Hypoxemia: PaO2 <60 mmHg, SaO2 <90% or supplemental O2 requirement to maintain SaO2> 90%
- Call Score ≥ 9 points
- FR> 30 / min
- PaO2 / FiO2 less than 200
- Intubated patients without deterioration of other organs (without acute kidney injury, without elevated transaminases).
- Progression of radiological findings of pneumonia.
- Patients with moderate or severe oxygenation disorder, with diaphragm of 200-100 and <100 respectively, who require supplemental oxygen at high flow (non-rebreathing mask or high flow cannula).
- Complete record of medical history, allergies, and medical conditions that preclude the use of prostaglandin E1 analogs have been ruled out.
- Voluntary participation in the study, demonstrating fullness through informed consent.
Exclusion Criteria:
- Allergy or sensitivity to PEG1 analog or components
- Arterial hypotension defined as blood pressure less than 90/60 mm of mercury or mean arterial pressure less than 65mm of mercury or BP requirement <80/50 mmHg or TAM 60 mmHg with norepinephrine requirement greater than 0.1 mcg / kg / min
- Severe hypertension defined as systolic blood pressure greater than or equal to 180 mm of mercury and / or diastolic blood pressure greater than or equal to 110 mm of mercury
- Bradycardia defined as heart rate less than 60 beats per minute
- Previous events of priapism or penile anatomical changes
- Sickle cell disease, multiple myeloma, leukemia, polycythemia vera, thrombocythemia predisposing to priapism
- Hemorrhagic diathesis
- Active peptic ulcer, trauma, or recent brain hemorrhage.
- Abnormal pulmonary venous return with obstruction
- Pregnancy: A pregnancy test will be performed upon admission of the patient to the study (if applicable).
- Heart failure with NYHA functional class> 1
- Hemodynamically relevant arrhythmia: That generates hypotension, chest pain, dysfunction, sensory disturbance or other signs of low output
- Mitral and / or aortic stenosis and / or insufficiency of either
- Unstable angina
- Acute Myocardial Infarction in the last 6 months
- Ischemic or hemorrhagic cerebrovascular event in the last 6 months
- Child B or C or decompensated liver cirrhosis
- Chronic kidney disease in renal replacement therapy
- Serious medical condition or laboratory findings that, in the investigator's judgment, may compromise patient safety during participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard therapeutic protocol
|
Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account. Among the alternatives proposed by the current clinical practice guidelines are:
|
Experimental: Standard Therapeutic Protocol + PGE1 Analog
Analog of PGE1 + Standard therapeutic protocol Standard medical treatment:
|
Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account. Among the alternatives proposed by the current clinical practice guidelines are:
Analog of PGE1: Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min. If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 6 month
|
Death during or at the end of the intervention
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypoxemia Resolution
Time Frame: 6 month
|
Sat O2> 90% to the environment
|
6 month
|
Days from admission to intensive care unit and administration of ANALOG PGE1
Time Frame: 6 month
|
Number of days from admission to intensive care unit until administration of ANALOG PGE1
|
6 month
|
ICU stay
Time Frame: 6 month
|
Specify number of days of ICU stay
|
6 month
|
Days with high flow oxygen
Time Frame: 6 month
|
Record days that the patient has received oxygen through a high flow system
|
6 month
|
Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG
Time Frame: 6 month
|
Number of days during which the patient was under invasive or non-invasive mechanical ventilation prior to the administration of PGE1 ANALOG
|
6 month
|
Evolution time of the disease
Time Frame: 6 month
|
Time from the onset of symptoms to the day of admission
|
6 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Vasodilator Agents
- Urological Agents
- Platelet Aggregation Inhibitors
- Alprostadil
Other Study ID Numbers
- CEIS-2020-089
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Standard therapeutic protocol
-
Hospital de Santa Maria, PortugalInstituto Politécnico de LeiriaCompleted
-
University of ValenciaSociedad Española de Cuidados Paliativos SECPALCompleted
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedSIRS (Systemic Inflammatory Response Syndrome(United States
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, France; Université... and other collaboratorsCompletedAlzheimer's DiseaseFrance
-
Kyle KnightCompleted
-
Thais Amanda RodriguesCompleted
-
UNICEF - VenezuelaRecruitingWasting | Acute Malnutrition in Childhood | Child MalnutritionVenezuela
-
Ergoterapia Manoegomito SaglUnknownSurgery | Distal Radius Fracture | CRPS (Complex Regional Pain Syndromes) | Wrist Fracture
-
Universidad Catolica de TemucoUnknown
-
Istituto Ortopedico RizzoliCompletedHip Osteoarthritis | Arthropathy of HipItaly